A tiny chip smaller than a pinky nail is letting people with severe age-related vision loss read words again, and European regulators just cleared it for sale.
Story Snapshot
- The PRIMA retinal implant, made by California-based Science Corporation, received a CE mark from European regulators, clearing it for commercial sale across roughly 30 countries.
- A 38-patient clinical trial found 84% of participants could read letters, numbers, and words after implantation, with an average gain of 25.5 letters on a standard eye chart.
- The device targets geographic atrophy, the advanced dry form of age-related macular degeneration that currently has no approved treatment for restoring sight.
- Results were published in the New England Journal of Medicine, and the company is now pursuing a path toward United States approval.
A Chip Built To Replace Dead Retina Cells
PRIMA is a two-millimeter photovoltaic chip surgeons place beneath the retina. It takes over for photoreceptor cells destroyed by advanced macular degeneration. Patients wear special glasses that beam infrared light onto the chip, which converts that signal into electrical pulses. Those pulses stimulate the retina’s remaining healthy neurons, sending a crude but usable image to the brain.
The condition PRIMA treats, geographic atrophy, is the end stage of dry macular degeneration. It slowly kills the light-sensing cells in the center of the retina. Patients keep their peripheral vision but lose the sharp central sight needed to read, recognize faces, or drive. Until now, doctors had no way to reverse that damage.
What The Clinical Trial Actually Showed
The pivotal European trial, known as PRIMAvera, enrolled 38 patients across 17 clinical sites in five countries. Researchers measured results using the ETDRS eye chart, the same standardized test eye doctors have used for decades to track vision changes. Patients averaged a gain of 25.5 letters, more than five lines on the chart, after twelve months.
Eighty-four percent of participants reported they could read letters, numbers, and words using their new prosthetic central vision, according to Science Corporation’s published trial summary. One patient gained 59 letters, more than eleven lines of improvement. Researchers also found no loss of the patients’ remaining natural peripheral vision, an important safety marker for any implant near the eye.
Separately, 81% of patients hit a slightly different benchmark researchers consider clinically meaningful, gaining at least ten letters or 0.2 logMAR units on standard vision tests. That threshold matters because it is the bar regulators and doctors typically use to decide whether a treatment produces a real, noticeable difference in daily life rather than a statistical blip.
Why Regulators And Investors Moved Fast
The European Union’s Conformité Européenne mark, commonly called CE mark, lets Science Corporation sell PRIMA across about 30 countries starting in Germany later this year. That approval came from the notified body DEKRA under the European Union’s Medical Device Regulation framework, the continent’s version of a safety and effectiveness review.
Science Corporation, founded by former Neuralink executives, has already raised significant funding around the device’s promise, and the company is now working toward a United States clinical pathway. The Food and Drug Administration (FDA) had earlier cleared feasibility studies for the technology’s predecessor, developed by French company Pixium Vision, showing federal regulators have tracked this device for years before Europe’s green light.
Science Corp's PRIMA retinal implant just earned a CE mark: the first treatment shown to restore functional central vision in geographic atrophy. In the NEJM trial, 84% of patients could read again. Founded by Duke alum Max Hodak. pic.twitter.com/vFiG7abwOO
— Duke Capital Partners (@DukeCapPartners) July 27, 2026
The Honest Limits Worth Knowing
No responsible reader should mistake this for restored eyesight the way most people picture it. Patients see a grainy, black-and-white, pixelated image through the implant, not natural color vision. It takes months of training with a specialist to learn how to interpret the prosthetic signal effectively.
The trial that supports these results was also small and open-label, meaning every patient knew they had received the implant, with no separate comparison group getting a placebo procedure. That is standard for first-in-human implant research, but it is worth remembering before anyone assumes this cure is universal or permanent. Longer-term data will matter as more patients get treated.
A Genuine Step Forward For An Untreatable Disease
Age-related macular degeneration affects millions of older Americans, and geographic atrophy has offered families almost nothing beyond magnifying glasses and low-vision aids. A device that lets a grandmother read a birthday card again is not a small thing, regardless of how pixelated the image looks. That is a genuine medical win worth celebrating without hype or spin.
The real test now shifts to America. If the Food and Drug Administration moves with the same rigor it has shown reviewing other implants, and if Science Corporation’s data holds up in a larger trial, this could reach United States patients within a couple of years. For now, Europe leads, and millions watching their central vision fade have a real reason for cautious hope.
eyewire.news, insidebci.com, theagenttimes.com, ft.com, youtube.com, retinalphysician.com, upmc.com, pmc.ncbi.nlm.nih.gov
© truthandliberty.com 2026. All rights reserved.
